EPO and chronic kidney disease: Compared with agents commonly used in treating anemia in CKD patients, daprodustat has certain potential advantages, such as avoiding the risk of supraphysiologic EPO levels and improving iron availability, which may reduce the need for iron replacement therapy (Lenihan and Winkelmayer, 2016).